<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
</B></FONT><B><FONT STYLE="font-size: 10pt">WASHINGTON, D.C. 20549</FONT></B><FONT STYLE="font-size: 10pt"> </FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">PURSUANT TO SECTION 13
OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">DATE OF REPORT (DATE OF
EARLIEST EVENT REPORTED):&nbsp;<B> February 29, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 18pt"><B><U>Skinny
Nutritional Corp.<BR>
</U></B></FONT><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">COMMISSION FILE NUMBER<B>:&nbsp;&nbsp;<U>0-51313</U></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Nevada</TD>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">88-0314792</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center">Three Bala Plaza East, Suite 101</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Bala Cynwyd, PA 19004</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt; text-align: center">(Address and zip code of principal executive offices)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-size: 10pt"><B><U>(610)
784-2000<BR>
</U></B>(Registrant&rsquo;s telephone number, including area code </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">CHECK THE APPROPRIATE BOX BELOW IF THE FORM
        8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>
        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>
        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>
        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>
        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><BR STYLE="mso-special-character: line-break">
</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><BR STYLE="mso-special-character: line-break">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 10%; vertical-align: top; font-weight: bold">Item 1.01</TD>
    <TD STYLE="width: 90%; padding-left: 8.8pt; font-weight: bold">Entry into a Material Definitive Agreement.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-left: 8.8pt; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD>As previously reported, in November 2011, Skinny Nutritional Corp. (the &ldquo;Company&rdquo;) commenced a private
    offering (the &ldquo;Unit Offering&rdquo;) pursuant to which it is offering an aggregate amount of $2,500,000 of units of
    the     Company&rsquo;s securities (the &ldquo;Units&rdquo;) on a &ldquo;best efforts&rdquo; basis. Each Unit consists of one
    (1)     Convertible Senior Subordinated Secured Note in the principal amount of $25,000 (the &ldquo;Convertible Note&rdquo;)
    and one     (1) Series A Common Stock Purchase Warrant (the &ldquo;Series A Warrant&rdquo;). &nbsp; <BR> <BR> On February 29,
    2012 and     March 1, 2012, the Company accepted subscriptions under the Subscription Agreement (the &ldquo;Subscription
    Agreement&rdquo;)     from additional accredited investors, pursuant to which the Company will sell and issue to the
    investors additional     Convertible Notes in the aggregate principal amount of $305,000 and Series A Warrants to purchase an
    aggregate of 10,166,666     shares of Common Stock in the final closings of the Unit Offering. The aggregate principal amount
    of the Convertible Notes     issued in the final closings is initially convertible into 10,166,666 shares of common
    stock.&nbsp;&nbsp; &nbsp; <BR> <BR>     The Convertible Notes are convertible into either (i) shares of the Company&rsquo;s
    Common Stock (the &ldquo;Conversion     Shares&rdquo;) at the initial conversion rate of $0.03 or (ii) the securities (the
    &ldquo;Conversion Securities&rdquo;) sold     by the Company in the next financing conducted by the Company (the &ldquo;Next
    Financing&rdquo;) at a conversion rate equal     to a 20% discount to the price at which the securities in the Next Financing
    are sold. In the event that the gross proceeds     realized by the Company in the Next Financing are at least $5,000,000,
    then each holder of a Convertible Note shall be     required to convert such Convertible Note into the Conversion Securities
    issued in the Next Financing. The conversion rate is     subject to adjustment as described in the Convertible Notes,
    including adjustment on a &ldquo;weighted-average&rdquo; basis     in the event that the Company issued additional shares of
    Common Stock or other equity securities at a purchase price below     the initial conversion rate. The principal amount of
    the Convertible Notes shall bear interest at the rate of 10% per annum     and shall have an initial maturity date of twelve
    (12) months. The Company shall have the right to extend the maturity date     for an additional twelve (12) month period
    provided it issues the purchasers additional Series A Warrants. The Convertible     Notes are secured obligations of the
    Company and will be secured by a lien on the Company&rsquo;s assets, which lien will be     subordinated to the senior
    indebtedness of the Company, in accordance with the terms of a security agreement entered into     between the Company and
    the investors.<BR> <BR>  The Series A Warrants shall permit the holders to purchase shares of the     Company&rsquo;s Common
    Stock at an initial per share exercise price of $0.05 for a period of five years. The exercise price     shall be subject to
    adjustment in the event that the Company issues additional common stock purchase warrants in the Next     Financing and such
    warrants have an exercise price less than the exercise price of the Series A Warrants. Each purchaser     shall be issued a
    Series A Warrant to purchase such number of Warrant Shares as is equal to 100% of the number of Conversion     Shares which
    may be issued upon conversion of the Convertible Note purchased by such purchaser, at the initial conversion     rate of such
    Convertible Note. &nbsp; <BR> <BR> In consideration for services rendered as selling agents in the Unit     Offering, the
    Company agreed to pay to the selling agents cash commissions of up to $24,400, or 8.0% of the gross proceeds
    received in the final closings of the Unit Offering, and agreed to issue five-year warrants to purchase an aggregate of
    1,016,666 shares of the Company&rsquo;s common stock at an exercise price of $0.05 per share (the &ldquo;Agent
    Warrants&rdquo;). &nbsp; <BR> <BR> Net proceeds from the sale of the securities in the final closings, after payment of
    offering expenses and commissions, are approximately $280,000 and total net proceeds from the entire Unit Offering are
    approximately $648,000. &nbsp;The Company intends to use the proceeds from the Offering for working capital and general
    corporate purposes. The securities being offered have not been registered under the Securities Act or any state securities
    laws and will be offered in reliance upon the exemption from registration set forth in Section 4(2) of the Securities Act or
    any state Regulation D, promulgated thereunder.&nbsp;Such shares may not be offered or sold in the United States absent
    registration or an applicable exemption from registration requirements.&nbsp;&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.8pt">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">Item 2.03</TD>
    <TD STYLE="padding-left: 8.8pt; font-weight: bold">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-left: 8.8pt; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 0in; padding-left: 0in">The information disclosed in Item&nbsp;1.01 of this Current Report on Form 8-K is incorporated by reference into this Item&nbsp;2.03.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-left: 8.8pt; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">Item&nbsp;3.02</TD>
    <TD STYLE="padding-left: 8.8pt; font-weight: bold">Unregistered Sales of Equity Securities.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 0in; padding-left: 0in">The information disclosed in Item&nbsp;1.01 of this Current Report on Form 8-K is incorporated by reference into this Item&nbsp;3.02. The sale and issuance of the Convertible Notes, Series A Warrants and Agent Warrants (and the issuance of shares of the Company&rsquo;s common stock upon exercise or conversion thereof) have been determined to be exempt from registration under the Securities Act of 1933, in reliance on Section&nbsp;4(2) thereof and Rule&nbsp;506 of Regulation&nbsp;D promulgated thereunder as a transaction by an issuer not involving a public offering, in which the investors are accredited and have acquired the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof. Such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.&nbsp;&nbsp;This disclosure does not constitute an offer to sell or the solicitation of an offer to buy any of the Company&rsquo;s securities, nor will there be any sales of these securities by the Company in any state or jurisdiction in which the offer, solicitation or sale would be unlawful.&nbsp;&nbsp;The disclosure is being issued pursuant to and in accordance with Rule 135c promulgated under the Securities Act of 1933.</TD></TR>
<TR>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding: 5pt 11.4pt 5pt 11.5pt; font-weight: bold"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 42%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 56%; font-weight: bold">Skinny Nutritional Corp.</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>By: &nbsp;/s/ Michael Salaman &nbsp;&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Michael Salaman</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: &nbsp;&nbsp;Chief Executive Officer</TD></TR>
<TR>
    <TD>&nbsp;Date: &nbsp;&nbsp;March &nbsp;6, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v304832_8-k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 18106}]
{"company-data": {"conformed-name": "Skinny Nutritional Corp.", "cik": "0001176325", "assigned-sic": "5141", "irs-number": "233100268", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51313", "film-number": "12671510"}, "business-address": {"street1": "3 BALA PLAZA EAST", "street2": "SUITE 117", "city": "BALA CYNWYD", "state": "PA", "zip": "19004", "phone": "610-784-2000"}, "mail-address": {"street1": "3 BALA PLAZA EAST", "street2": "SUITE 117", "city": "BALA CYNWYD", "state": "PA", "zip": "19004"}, "former-company": {"former-conformed-name": "CREATIVE ENTERPRISES INTERNATIONAL INC", "date-changed": "20020625"}}
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13
OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF
EARLIEST EVENT REPORTED):
February 29, 2012
Skinny
Nutritional Corp.
(Exact name of registrant as specified in its charter)
COMMISSION FILE NUMBER
:
0-51313
Nevada
88-0314792
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
Three Bala Plaza East, Suite 101
Bala Cynwyd, PA 19004
(Address and zip code of principal executive offices)
(610)
784-2000
(Registrant's telephone number, including area code
CHECK THE APPROPRIATE BOX BELOW IF THE FORM
        8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement.
As previously reported, in November 2011, Skinny Nutritional Corp. (the "Company") commenced a private
    offering (the "Unit Offering") pursuant to which it is offering an aggregate amount of $2,500,000 of units of
    the     Company's securities (the "Units") on a "best efforts" basis. Each Unit consists of one
    (1)     Convertible Senior Subordinated Secured Note in the principal amount of $25,000 (the "Convertible Note")
    and one     (1) Series A Common Stock Purchase Warrant (the "Series A Warrant").
On February 29,
    2012 and     March 1, 2012, the Company accepted subscriptions under the Subscription Agreement (the "Subscription
    Agreement")     from additional accredited investors, pursuant to which the Company will sell and issue to the
    investors additional     Convertible Notes in the aggregate principal amount of $305,000 and Series A Warrants to purchase an
    aggregate of 10,166,666     shares of Common Stock in the final closings of the Unit Offering. The aggregate principal amount
    of the Convertible Notes     issued in the final closings is initially convertible into 10,166,666 shares of common
    stock.
The Convertible Notes are convertible into either (i) shares of the Company's
    Common Stock (the "Conversion     Shares") at the initial conversion rate of $0.03 or (ii) the securities (the
    "Conversion Securities") sold     by the Company in the next financing conducted by the Company (the "Next
    Financing") at a conversion rate equal     to a 20% discount to the price at which the securities in the Next Financing
    are sold. In the event that the gross proceeds     realized by the Company in the Next Financing are at least $5,000,000,
    then each holder of a Convertible Note shall be     required to convert such Convertible Note into the Conversion Securities
    issued in the Next Financing. The conversion rate is     subject to adjustment as described in the Convertible Notes,
    including adjustment on a "weighted-average" basis     in the event that the Company issued additional shares of
    Common Stock or other equity securities at a purchase price below     the initial conversion rate. The principal amount of
    the Convertible Notes shall bear interest at the rate of 10% per annum     and shall have an initial maturity date of twelve
    (12) months. The Company shall have the right to extend the maturity date     for an additional twelve (12) month period
    provided it issues the purchasers additional Series A Warrants. The Convertible     Notes are secured obligations of the
    Company and will be secured by a lien on the Company's assets, which lien will be     subordinated to the senior
    indebtedness of the Company, in accordance with the terms of a security agreement entered into     between the Company and
    the investors.
The Series A Warrants shall permit the holders to purchase shares of the     Company's Common
    Stock at an initial per share exercise price of $0.05 for a period of five years. The exercise price     shall be subject to
    adjustment in the event that the Company issues additional common stock purchase warrants in the Next     Financing and such
    warrants have an exercise price less than the exercise price of the Series A Warrants. Each purchaser     shall be issued a
    Series A Warrant to purchase such number of Warrant Shares as is equal to 100% of the number of Conversion     Shares which
    may be issued upon conversion of the Convertible Note purchased by such purchaser, at the initial conversion     rate of such
    Convertible Note.
In consideration for services rendered as selling agents in the Unit     Offering, the
    Company agreed to pay to the selling agents cash commissions of up to $24,400, or 8.0% of the gross proceeds
    received in the final closings of the Unit Offering, and agreed to issue five-year warrants to purchase an aggregate of
    1,016,666 shares of the Company's common stock at an exercise price of $0.05 per share (the "Agent
    Warrants").
Net proceeds from the sale of the securities in the final closings, after payment of
    offering expenses and commissions, are approximately $280,000 and total net proceeds from the entire Unit Offering are
    approximately $648,000.  The Company intends to use the proceeds from the Offering for working capital and general
    corporate purposes. The securities being offered have not been registered under the Securities Act or any state securities
    laws and will be offered in reliance upon the exemption from registration set forth in Section 4(2) of the Securities Act or
    any state Regulation D, promulgated thereunder. Such shares may not be offered or sold in the United States absent
    registration or an applicable exemption from registration requirements.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
Item 3.02
Unregistered Sales of Equity Securities.
The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The sale and issuance of the Convertible Notes, Series A Warrants and Agent Warrants (and the issuance of shares of the Company's common stock upon exercise or conversion thereof) have been determined to be exempt from registration under the Securities Act of 1933, in reliance on Section 4(2) thereof and Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering, in which the investors are accredited and have acquired the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof. Such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  This disclosure does not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor will there be any sales of these securities by the Company in any state or jurisdiction in which the offer, solicitation or sale would be unlawful.  The disclosure is being issued pursuant to and in accordance with Rule 135c promulgated under the Securities Act of 1933.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
Skinny Nutritional Corp.
By:  /s/ Michael Salaman
Name: Michael Salaman
Title:   Chief Executive Officer
Date:   March  6, 2012